Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Thiéblemont, Catherine; Phillips, Tycel; Ghesquières, Hervé; Y. Cheah, Chan; Roost Clausen, Michael; Cunningham, David; Rok, Young; Feldman, Tatyana; Gasiorowski, Robin; Jurczak, Wojciech; Min Kim, Tae; Lewis, David; van der Poel, Marjolein; Poon, Michelle; Cota Stirner, Mariana; Kilavuz, Nurgul; Chiu, Christopher; Chen, Menghui; Sacchi, Mariana; Elliott, Brian; Ahmadi, Tahamtan; Hutchings, Martin; J. Lugtenburg, Pieternella

doi:10.1200/jco.22.01725

Public

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Published in Journal of Clinical Oncology • Dec 22, 2022

Authors:

Catherine Thiéblemont

Tycel Phillips

Hervé Ghesquières

Abstract

PURPOSE: B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS: large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcorita...

Subject

Medicine

Bispecific antibody

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!